Movement Disorders

Filter Your Results

 

News

 

17 New Genes Linked to Parkinson’s Disease

Thursday, September 14, 2017—A new study has discovered 17 novel genetic variants associated with Parkinson’s disease, several of which are considered targets for intervention. Published in Nature G…

Austedo Approved for Treatment of Tardive Dyskinesia

Thursday, August 31, 2017—The FDA has approved Austedo (deutetrabenazine, Teva Pharmaceutical Industries Ltd.) tablets for the treatment of tardive dyskinesia in adults. The approval was based on …

AstraZeneca and Takeda Strike $400 Million Development Deal for Investigational Parkinson’s Agent

Tuesday, August 29, 2017—AstraZeneca and Takeda Pharmaceutical Company Limited will jointly develop and commercialize an investigational alpha-synuclein antibody currently in development for the treat…

Technology and Parkinson’s Disease: New Solutions for Old Problems

Sanaz Attaripour Isfahani, MD and Jill Giordano Farmer, DO, MPH

July/August 2017—From digital innovations to practical solutions, technology can offer the possibility of improved quality of life for individuals with Parkinson’s disease.

Sage Bionetworks Launches DREAM Challenge to Identify Best Uses for Remote Sensing Devices

Thursday, July 13, 2017—Sage Bionetworks has launched the Parkinson’s Disease Digital Biomarker DREAM Challenge, the first in a series of open, crowd-sourced analytical projects to help researc…

Visual System Changes May Represent an Early Signal of Parkinson’s Disease

Wednesday, July 12, 2017—Changes in the intracranial visual system may be a signal of Parkinson’s disease (PD), according to new findings published in Radiology. Using MRI, researchers evaluated…

Phase 3 Results Published for Investigational Levodopa-Induced Dyskinesia Treatment

Wednesday, June 14, 2017—Results from the Phase 3 EASE LID clinical trial, published online in JAMA Neurology, show that the investigational ADS-5102 (amantadine, Adamas Pharmaceuticals) reduces levod…

Anti-Alpha-Synuclein Antibody Shows Early Potential as Parkinson’s DMT

Friday, June 09, 2017—PRX002, an investigational monoclonal antibody, may inhibit cell-to-cell transmission of alpha-synuclein and modify disease progression in Parkinson’s disease (PD), acco…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.

 
  • BRYN MAWR COMMUNICATIONS III, LLC